Amino Acid, Peptide, or Protein – Page 7

CDC Advisors Shift COVID-19 Vaccine Guidance to Individual Decision-Making

1 month ago talkbio0Tagged ACIP, Centers for Disease Control and Prevention (U.S.), Consultation, COVID19 (disease), individual choice, Provider, Recommendation, Vaccines

CDC; COVID-19 vaccine; vaccine recommendation; individual choice; ACIP; provider consultation

FDA Approves Stealth BioTherapeutics’ Forzinity as First Treatment for Barth Syndrome After Rejection and Delay

1 month ago talkbio0Tagged 3-Methylglutaconic aciduria type 2, Abnormality of mitochondrial metabolism, Accelerated, Approved, Elamipretide, Forzinity, Infrequent, Stealth BioTherapeutics, United States Food and Drug Administration

FDA approval; Stealth BioTherapeutics; Forzinity; elamipretide; Barth syndrome; rare disease; mitochondrial dysfunction; accelerated approval

FDA Grants Accelerated Approval to Stealth BioTherapeutics’ Forzinity, the First Treatment for Barth Syndrome

1 month ago talkbio0Tagged 3-Methylglutaconic aciduria type 2, Accelerated, Approved, Clinical Trials, Elamipretide, Forzinity, Infrequent, Mitochondrial Diseases, Pediatric Disorder, Stealth BioTherapeutics, United States Food and Drug Administration

FDA approval; Stealth BioTherapeutics; Forzinity; elamipretide; Barth syndrome; mitochondrial disease; accelerated approval; rare disease; pediatric disease; clinical trial

Merck Wins FDA Approval for Subcutaneous Keytruda as Exclusivity Challenges Approach

1 month ago talkbio0Tagged Approved, Biosimilars, checkpoint inhibitors, Immunotherapy for cancer, Keytruda, Keytruda Qlex, Merck, patent expiration, Solid Neoplasm, Subcutaneous Injections, United States Food and Drug Administration

Merck; Keytruda; subcutaneous injection; FDA approval; Keytruda Qlex; patent expiration; biosimilars; checkpoint inhibitors; solid tumors; cancer immunotherapy

ACIP Vote Restricts Combined MMRV Vaccine for Children Under 4, Raising Access Concerns

1 month ago talkbio0Tagged ACIP, CDC, CDC vaccine recommendation, Chickenpox, Child, Childhood, Immunization, measles, MMRV vaccine, Mumps, Rubella, vaccine access, Vaccines

ACIP; MMRV vaccine; measles; mumps; rubella; varicella; childhood immunization; Vaccines for Children (VFC) program; CDC vaccine recommendation; vaccine access

Novo Nordisk Awaits FDA Decision on Oral Wegovy Pill for Obesity

1 month ago talkbio0Tagged Approved, Cardiovascular Risk, Contraceptives, Oral, Glucagon-Like Peptide 1, Nordisk, Obesity, oral semaglutide, United States Food and Drug Administration, Wegovy, Weight Loss

Novo Nordisk; Wegovy; oral semaglutide; FDA approval; obesity treatment; GLP-1 pill; weight loss; cardiovascular risk

VectorY Strikes $1.2B Option and License Pact with Shape Therapeutics for Brain-Penetrant Gene Therapy Delivery

1 month ago talkbio0Tagged Alzheimer 's disease, Antibodies, biobucks, brain-penetrant delivery, Capsid, Dependovirus, gene therapy, Huntington Disease, milestone payments, Neurodegenerative Disorders, pipeline, SHP-DB1, vectorized, VectorY

VectorY Therapeutics; Shape Therapeutics; SHP-DB1; adeno-associated virus (AAV) capsid; brain-penetrant delivery; gene therapy; neurodegenerative diseases; Huntington’s disease; Alzheimer’s disease; biobucks; pipeline; milestone payments; vectorized antibodies

Lilly’s Mounjaro Shows Strong Results in Youth Type 2 Diabetes, Paving Way for Expansion

1 month ago talkbio0Tagged Adolescent (age group), Body mass index procedure, Child, Clinical Trials, Diabetes Mellitus, Non-Insulin-Dependent, eli lilly, Hemoglobin A1c measurement, Mounjaro, SURPASS-PEDS

Mounjaro; tirzepatide; type 2 diabetes; children; adolescents; SURPASS-PEDS; A1C reduction; BMI reduction; clinical trial; Eli Lilly

Roche Acquires 89bio with $2.4 Billion Buyout to Enter FGF21 MASH Therapeutics Space

1 month ago talkbio0Tagged Acquisition, cardiometabolic diseases, Conditional, fibroblast growth factor 21, Liver diseases, MASH, metabolic dysfunction-associated steatohepatitis, pegozafermin, Roche (company)

Roche; 89bio; acquisition; FGF21; pegozafermin; MASH; metabolic dysfunction-associated steatohepatitis; liver disease; biotech; contingent value rights; cardiometabolic diseases

Novo Nordisk and Bristol Myers Squibb Announce Major Layoffs in New Jersey

1 month ago talkbio0Tagged Drug Industry, layoffs, Myers, Nordisk, Ozempic, restructuring, Wegovy

Novo Nordisk; Bristol Myers Squibb; layoffs; New Jersey; pharmaceutical industry; restructuring; job cuts; Ozempic; Wegovy; workforce reduction